Key regions: France, Europe, United Kingdom, Brazil, India
The demand for oncology drugs in Iran has been steadily increasing in recent years.
Customer preferences: Iran has a growing population, and with an aging population, the incidence of cancer is increasing. Patients are increasingly seeking more advanced treatments, and as a result, there is a growing demand for oncology drugs. Additionally, there is a growing awareness of cancer and its treatment options among the Iranian population.
Trends in the market: In recent years, there has been an increase in the number of pharmaceutical companies entering the Iranian market. This has led to increased competition, which has in turn led to lower prices for oncology drugs. Additionally, there has been a trend towards the development of targeted therapies, which are more effective and have fewer side effects than traditional chemotherapy. This has led to an increase in the use of targeted therapies in the treatment of cancer.
Local special circumstances: Iran has a well-established healthcare system, with a large number of hospitals and clinics. However, the country is facing economic sanctions, which have had an impact on the availability of certain drugs. This has led to some shortages of oncology drugs in the country. Additionally, there are some challenges in terms of access to healthcare in rural areas, which can make it difficult for patients to receive the treatment they need.
Underlying macroeconomic factors: The Iranian economy has been struggling in recent years, with high inflation and unemployment rates. This has led to some challenges in terms of affordability of healthcare for some patients. Additionally, the economic sanctions have had an impact on the availability of certain drugs in the country, which has led to some shortages and increased prices. Despite these challenges, the demand for oncology drugs in Iran is expected to continue to grow in the coming years.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
